Commence Bio is an intriguing company that has recently entered the mesenchymal stem cell (MSC) marketplace. Commence Bio came across my radar screen earlier this year right around the time that it announced the name change, as highlighted in the company press release below.
The Gems Keep Coming: Top 10 Quotes from Day 2 of World Stem Cell Summit (#WSCS15)
*Photo courtesy of Mayo Clinic. Source: https://flic.kr/p/BZSvVA
Friday was an another mind-blowing day at the World Stem Cell Summit (#WSCS15) in Atlanta, GA, affectionately called “Fantastic Friday” because of the packed schedule and high-energy content. The World Stem Cell Summit brings together more than 1,200 intelligent minds, putting brilliant speakers on stage and packing rooms with curious and eager listeners.
Yesterday, I released a post titled “Top 10 Quotes from Day 1 of the World Stem Cell Summit.” Again today, there the speakers were spinning gems of wisdom and it doesn’t seem appropriate to let them fade without adequate appreciation. On that note, here are my top 10 favorite quotes from today, Day 2 of the World Stem Cell Summit 2015.
[Read more…]
Nohla Therapeutics Launches with Major US Cancer Research Institute Deal, Substantial Investment Round, and Key Appointments
General enquiries
Nohla Therapeutics Inc.
Benjamin Bergo, +1 206 310 5560 (US)
CEO
[email protected]
Investors
Nohla Therapeutics Inc.
Michael Sistenich, +61 (0)413 087 194 (AUS)
Head of Corporate Development
[email protected]
Media (Australia)
Buchan Consulting
Ben Walsh, +61 (0)468 422 865 (AUS)
[email protected]
Media (US)
WE
Ben Navon, +1 (617) 234-4104 (US)
[email protected]
Want to be better informed than your competition? Get future stem cell industry updates.
About Us
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.
Astella Acquires Ocata Therapeutics for $379M
Astellas Pharma announced it is acquiring Ocata Therapeutics for $379M. Headquartered in Tokyo, Japan, Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year, while Ocata is headquartered in Marlborough, Massachusetts. Astellas’ cash flow is essential, because the company has agreed to pay $8.50 a share for Ocata, a 79% premium over the stock price last Friday. [Read more…]
Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform
Cynata Therapeutics is a regenerative medicine company, listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).
UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.
Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation. [Read more…]